Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Solvonis TherapeuticsFRA:J4I -25.00% EV-to-FCF is -2.99 as of Jul. 22, 2026. The stock has 4 warning signs investors should review. Among 1,736 Industrial Products companies, Solvonis Therapeutics ranks worse than 57603.63% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Solvonis Therapeutics's Enterprise Value is €11.28 Mil.
Solvonis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.78 Mil. Therefore, Solvonis Therapeutics's EV-to-FCF for today is -2.99.
The historical rank and industry rank for Solvonis Therapeutics's EV-to-FCF or its related term are showing as below:
FRA:J4I'
s EV-to-FCF Range Over the Past 10 Years
Min: -129.92 Med: -0.14 Max: 0.33
Current: -3.03
During the past 8 years, the highest EV-to-FCF of Solvonis Therapeutics was 0.33. The lowest was -129.92. And the median was -0.14.
FRA:J4I's EV-to-FCF is ranked worse than 100% of 1736
companies
in the Industrial Products industry
Industry Median: 23.72
vs FRA:J4I: -3.03
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Solvonis Therapeutics's PE Ratio (TTM) for today is calculated as:
Solvonis Therapeutics's share price for today is €0.0015.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Industrial Machinery subindustry, Solvonis Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solvonis Therapeutics EV-to-FCF vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, Solvonis Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Solvonis Therapeutics's EV-to-FCF falls into.
Solvonis Therapeutics's current Enterprise Value is €11.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Solvonis Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solvonis Therapeutics (FRA:J4I) has a EV-to-FCF of -2.99 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Solvonis Therapeutics and its competitors. According to the industry distribution chart, Solvonis Therapeutics ranks #999999 out of 1736 companies in the Industrial Products industry.
Is Solvonis Therapeutics' EV-to-FCF too high?
Solvonis Therapeutics' current EV-to-FCF is -2.99. Based on the distribution chart, Solvonis Therapeutics ranks #999999 out of 1736 companies in the Industrial Products industry, which is in the bottom quartile relative to peers.
How does Solvonis Therapeutics' EV-to-FCF compare to GEV and ETN?
According to the Industrial Products industry distribution chart, Solvonis Therapeutics ranks #999999 out of 1736 companies for EV-to-FCF. This places Solvonis Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 23.72. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for an Industrial Products company?
The median EV-to-FCF among Industrial Products companies is 23.72, based on 1,736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Solvonis Therapeutics and its competitors. For the Industrial Products industry, the median EV-to-FCF is 23.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solvonis Therapeutics's current EV-to-FCF is -2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solvonis Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Solvonis Therapeutics (FRA:J4I) is currently considered Possible Value Trap. The stock's GF Value™ is €0.01, compared to a current price of €0.00 — trading 85% below its estimated fair value. The current EV-to-FCF is -2.99. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Solvonis Therapeutics (FRA:J4I), the current EV-to-FCF is -2.99 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry. The products in company's pipeline include SVN-001, SVN-002, SVN-015. SVN-114, and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J4I has been successfully added to your 
